![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Baseline HCV NS5A Resistance-Associated Variants Do Not Impact SVR12 Rates in Non-Cirrhotic and Post-Liver Transplant Patients With Genotype 1 Infection Treated With Daclatasvir and Sofosbuvir With or Without Ribavirin for 12 Weeks: An Integrated Analysis
|
|
|
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
McPhee F,1 Hernandez D,1 Zhou N,1 Ueland J,1 Vellucci V,1 Hartman-Neumann S,1 Yang X,1 Han Z,1 Yu F,1 Yang R,2 Noviello S2
1Bristol-Myers Squibb Research and Development, Wallingford, CT; 2Bristol-Myers Squibb Research and Development, Princeton, NJ
![HIV1.gif](../../2016/images/011516/011516-3/HIV1.gif)
![HIV2.gif](../../2016/images/011516/011516-3/HIV2.gif)
![HIV3.gif](../../2016/images/011516/011516-3/HIV3.gif)
![HIV4.gif](../../2016/images/011516/011516-3/HIV4.gif)
![HIV5.gif](../../2016/images/011516/011516-3/HIV5.gif)
![HIV6.gif](../../2016/images/011516/011516-3/HIV6.gif)
![HIV7.gif](../../2016/images/011516/011516-3/HIV7.gif)
![HIV8.gif](../../2016/images/011516/011516-3/HIV8.gif)
![HIV9.gif](../../2016/images/011516/011516-3/HIV9.gif)
![HIV10.gif](../../2016/images/011516/011516-3/HIV10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|